12.01.2020, 1019 Zeichen

Valneva: Austrian Frensch biotech company Valneva SE announced that an End Of Phase 2 (EOP2) meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 24, 2020 for its single-shot chikungunya vaccine candidate, VLA1553. The Company plans to present its plan for Phase 3 clinical studies and licensure. VLA1553 has been awarded Fast Track designation by the FDA and may be eligible for a Priority Review Voucher. Wolfgang Bender, chief medical officer of Valneva, commented: “We are extremely pleased that the FDA has accepted our proposal for an EOP2 meeting. Subject to the outcome we may commence Phase 3 clinical trials within a few months. We are strongly committed to advancing VLA1553, currently the only chikungunya vaccine candidate in clinical development showing fully sustained titers one year after a single vaccination, through the accelerated approval.”
Valneva: weekly performance: 9.29%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/01/2020)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S16/14: Stefan Scharff

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, UBM, Palfinger, Immofinanz, Addiko Bank, CA Immo, SBO, Porr, Rosenbauer, EuroTeleSites AG, Frequentis, Kostad, Linz Textil Holding, Marinomed Biotech, Wiener Privatbank, Warimpex, Agrana, Amag, EVN, Flughafen Wien, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, E.ON , BASF, Zalando, Mercedes-Benz Group, Allianz, Hannover Rück.

---